Posted 9th January 2019 by Jane Williams
Bas Trietsch is the CTO and co-founder of MIMETAS and co-inventor of the OrganoPlate. As CTO he currently drives the continued product development of the OrganoPlate and its peripheral equipment.
Here, Bas talks about what the future holds for organ-on-a-chip and other breakthroughs technologies in biology.
Posted 17th December 2018 by Jane Williams
As industry developments continue to improve, the potential for personalised medicine and the possibility of individual diagnosis is on the horizon. These slides, from the Precision Medicine & Biomarkers Leaders Summit: Europe are now available from Andres Hurtado-Lorenzo, Thorsten Gutjahr & Thomas Skot Jensen.
Posted 20th November 2017 by Jane Williams
Recent step change advances in sequencing technologies have delivered a near-complete lexicon of genomic cancer drivers. In parallel, progress in synthetic chemistry has facilitated the assembly of a broad armamentarium of molecularly-targeted therapies. However, whilst immunotherapy agents have produced notable benefits for subgroups of patients, the impact of molecularly-targeted therapies have been relatively modest.
Further unlocking the undeniable power of genomics in cancer will involve both the systematic removal of barriers and the avoidance of distractions that obscure progress. Both of which are discussed here.